CellaVision AB (publ) (FRA:C26)
Germany
· Delayed Price · Currency is EUR | Market Cap | 425.48M |
| Revenue (ttm) | 68.94M |
| Net Income (ttm) | 14.02M |
| Shares Out | n/a |
| EPS (ttm) | 0.59 |
| PE Ratio | 30.35 |
| Forward PE | 25.81 |
| Dividend | 0.23 (1.27%) |
| Ex-Dividend Date | May 7, 2025 |
| Volume | n/a |
| Average Volume | 408 |
| Open | 17.68 |
| Previous Close | 17.60 |
| Day's Range | 17.68 - 17.70 |
| 52-Week Range | 13.10 - 25.95 |
| Beta | n/a |
| RSI | 60.64 |
| Earnings Date | Jul 18, 2025 |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers, instruments; and hardware products include in vitro diagnostics IVD for laboratories; as well as its portfolio includes smear makers, stainers, stains, and staining protocols; DIFF-Line is a hematology lab that handles a smaller amount daily blood samples and consists three instruments for smearing, staining, and analyzing ... [Read more]
Financial Performance
In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.
Financial numbers in SEK Financial StatementsNews
3 Scandinavian Companies With Strong Margin Growth
According to the All-in-One Screener, a Premium feature of GuruFocus, three Scandinavian companies with strong margin growth as of Monday are CellaVision AB (OSTO:CEVI), Fenix Outdoor International Lt...